OptimizeRx Competitors

OptimizeRx (NASDAQ:OPRX) and EVO Payments (NASDAQ:EVOP) are both computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

OptimizeRx has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, EVO Payments has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500.

Insider & Institutional Ownership

58.3% of OptimizeRx shares are owned by institutional investors. Comparatively, 52.7% of EVO Payments shares are owned by institutional investors. 8.1% of OptimizeRx shares are owned by company insiders. Comparatively, 51.0% of EVO Payments shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for OptimizeRx and EVO Payments, as provided by MarketBeat.

OptimizeRx currently has a consensus target price of $53.3333, indicating a potential upside of 34.88%. EVO Payments has a consensus target price of $24.00, indicating a potential downside of 12.70%. Given OptimizeRx's stronger consensus rating and higher possible upside, equities analysts plainly believe OptimizeRx is more favorable than EVO Payments.

Profitability

This table compares OptimizeRx and EVO Payments' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares OptimizeRx and EVO Payments' gross revenue, earnings per share and valuation.

OptimizeRx has higher earnings, but lower revenue than EVO Payments. OptimizeRx is trading at a lower price-to-earnings ratio than EVO Payments, indicating that it is currently the more affordable of the two stocks.

Summary

EVO Payments beats OptimizeRx on 7 of the 13 factors compared between the two stocks.

OptimizeRx (NASDAQ:OPRX) and TechTarget (NASDAQ:TTGT) are both small-cap computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

OptimizeRx has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, TechTarget has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Insider & Institutional Ownership

58.3% of OptimizeRx shares are owned by institutional investors. Comparatively, 89.6% of TechTarget shares are owned by institutional investors. 8.1% of OptimizeRx shares are owned by company insiders. Comparatively, 16.4% of TechTarget shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for OptimizeRx and TechTarget, as provided by MarketBeat.

OptimizeRx currently has a consensus target price of $53.3333, indicating a potential upside of 34.88%. TechTarget has a consensus target price of $42.6667, indicating a potential downside of 37.75%. Given OptimizeRx's higher possible upside, equities analysts plainly believe OptimizeRx is more favorable than TechTarget.

Profitability

This table compares OptimizeRx and TechTarget's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares OptimizeRx and TechTarget's gross revenue, earnings per share and valuation.

TechTarget has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than TechTarget, indicating that it is currently the more affordable of the two stocks.

Summary

TechTarget beats OptimizeRx on 10 of the 12 factors compared between the two stocks.

OptimizeRx (NASDAQ:OPRX) and NIC (NASDAQ:EGOV) are both small-cap computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

OptimizeRx has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, NIC has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.

Insider & Institutional Ownership

58.3% of OptimizeRx shares are owned by institutional investors. Comparatively, 89.7% of NIC shares are owned by institutional investors. 8.1% of OptimizeRx shares are owned by company insiders. Comparatively, 2.7% of NIC shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for OptimizeRx and NIC, as provided by MarketBeat.

OptimizeRx currently has a consensus target price of $53.3333, indicating a potential upside of 34.88%. NIC has a consensus target price of $27.75, indicating a potential upside of 1.09%. Given OptimizeRx's higher possible upside, equities analysts plainly believe OptimizeRx is more favorable than NIC.

Profitability

This table compares OptimizeRx and NIC's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares OptimizeRx and NIC's gross revenue, earnings per share and valuation.

NIC has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than NIC, indicating that it is currently the more affordable of the two stocks.

Summary

NIC beats OptimizeRx on 9 of the 13 factors compared between the two stocks.

OptimizeRx (NASDAQ:OPRX) and Cardtronics (NASDAQ:CATM) are both small-cap computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

OptimizeRx has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Cardtronics has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500.

Insider & Institutional Ownership

58.3% of OptimizeRx shares are owned by institutional investors. 8.1% of OptimizeRx shares are owned by company insiders. Comparatively, 19.8% of Cardtronics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for OptimizeRx and Cardtronics, as provided by MarketBeat.

OptimizeRx currently has a consensus target price of $53.3333, indicating a potential upside of 34.88%. Cardtronics has a consensus target price of $41.40, indicating a potential upside of 1.69%. Given OptimizeRx's stronger consensus rating and higher possible upside, equities analysts plainly believe OptimizeRx is more favorable than Cardtronics.

Profitability

This table compares OptimizeRx and Cardtronics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares OptimizeRx and Cardtronics' gross revenue, earnings per share and valuation.

Cardtronics has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Cardtronics, indicating that it is currently the more affordable of the two stocks.

Summary

Cardtronics beats OptimizeRx on 9 of the 13 factors compared between the two stocks.

OptimizeRx (NASDAQ:OPRX) and Repay (NASDAQ:RPAY) are both small-cap computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

OptimizeRx has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Repay has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Insider & Institutional Ownership

58.3% of OptimizeRx shares are owned by institutional investors. Comparatively, 85.5% of Repay shares are owned by institutional investors. 8.1% of OptimizeRx shares are owned by company insiders. Comparatively, 16.5% of Repay shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for OptimizeRx and Repay, as provided by MarketBeat.

OptimizeRx currently has a consensus target price of $53.3333, indicating a potential upside of 34.88%. Repay has a consensus target price of $27.50, indicating a potential upside of 13.78%. Given OptimizeRx's stronger consensus rating and higher possible upside, equities analysts plainly believe OptimizeRx is more favorable than Repay.

Profitability

This table compares OptimizeRx and Repay's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares OptimizeRx and Repay's gross revenue, earnings per share and valuation.

OptimizeRx has higher earnings, but lower revenue than Repay.

Summary

Repay beats OptimizeRx on 7 of the 12 factors compared between the two stocks.

OptimizeRx (NASDAQ:OPRX) and CBIZ (NYSE:CBZ) are both small-cap computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

OptimizeRx has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, CBIZ has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.

Insider & Institutional Ownership

58.3% of OptimizeRx shares are owned by institutional investors. Comparatively, 86.4% of CBIZ shares are owned by institutional investors. 8.1% of OptimizeRx shares are owned by company insiders. Comparatively, 7.4% of CBIZ shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for OptimizeRx and CBIZ, as provided by MarketBeat.

OptimizeRx currently has a consensus target price of $53.3333, indicating a potential upside of 34.88%. Given OptimizeRx's higher possible upside, equities analysts plainly believe OptimizeRx is more favorable than CBIZ.

Profitability

This table compares OptimizeRx and CBIZ's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares OptimizeRx and CBIZ's gross revenue, earnings per share and valuation.

CBIZ has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than CBIZ, indicating that it is currently the more affordable of the two stocks.

Summary

CBIZ beats OptimizeRx on 9 of the 13 factors compared between the two stocks.